Disease · MONDO_0005770
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Famciclovir vs Valacyclovir: serious adverse events | 2 of 371 | 1 of 385 | 756 | NCT00306787 | Trial comparisons |
| Valaciclovir 1g QD vs Placebo: deaths from any cause | 1 of 255 | 0 of 128 | 383 | NCT00158860 | Trial comparisons |
| Valaciclovir 1g QD vs Placebo: serious adverse events | 3 of 255 | 4 of 128 | 383 | NCT00158860 | Trial comparisons |
| Famciclovir 1000 mg vs Placebo Comparator: serious adverse events | 2 of 206 | 1 of 98 | 304 | NCT00477334 | Trial comparisons |
| Famciclovir 1000 mg vs Placebo Comparator: Number of Participants With a Second Recurrence of Genital Herpes in the Follow-up Period | 141 of 185 | 75 of 92 | 277 | NCT00477334 | Trial comparisons |
| Famciclovir 125 mg vs Aciclovir 200 mg: serious adverse events | 0 of 75 | 0 of 75 | 150 | NCT01281007 | Trial comparisons |
| HerpV + QS-21 vs Placebo: serious adverse events | 3 of 70 | 0 of 10 | 80 | NCT01687595 | Trial comparisons |
| Episodic Treatment Arm vs Suppressive Therapy Arm: serious adverse events | 0 of 35 | 0 of 37 | 72 | NCT00495716 | Trial comparisons |
| HerpV + QS-21 vs Placebo: Number of Participants With Peripheral Blood Mononuclear Cell Immune Response at Any Time | 46 of 61 | 1 of 8 | 69 | NCT01687595 | Trial comparisons |
| HerpV + QS-21 vs Placebo: Number of Participants With CD8+ Immune Response at Any Time | 32 of 61 | 2 of 8 | 69 | NCT01687595 | Trial comparisons |
| Standard Dose vs High-dose: serious adverse events | 0 of 27 | 0 of 31 | 58 | NCT00362297 | Trial comparisons |
| Arm 1: Valacyclovir vs Arm 2: Placebo: serious adverse events | 0 of 16 | 0 of 15 | 31 | NCT01453075 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005770/comparisons